- Home
- INKT vs BCAB Comparison
INKT vs BCAB Comparison
Compare INKT & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- BCAB
- Stock Information
- Founded
- INKT 2017
- BCAB 2007
- Country
- INKT United States
- BCAB United States
- Employees
- INKT N/A
- BCAB N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- INKT Health Care
- BCAB Health Care
- Exchange
- INKT Nasdaq
- BCAB Nasdaq
- Market Cap
- INKT 33.6M
- BCAB 27.0M
- IPO Year
- INKT 2021
- BCAB 2020
- Fundamental
- Price
- INKT $7.25
- BCAB $0.32
- Analyst Decision
- INKT Strong Buy
- BCAB Buy
- Analyst Count
- INKT 2
- BCAB 2
- Target Price
- INKT $37.50
- BCAB $1.00
- AVG Volume (30 Days)
- INKT 5.5K
- BCAB 534.2K
- Earning Date
- INKT 05-13-2025
- BCAB 05-13-2025
- Dividend Yield
- INKT N/A
- BCAB N/A
- EPS Growth
- INKT N/A
- BCAB N/A
- EPS
- INKT N/A
- BCAB N/A
- Revenue
- INKT N/A
- BCAB $11,000,000.00
- Revenue This Year
- INKT N/A
- BCAB N/A
- Revenue Next Year
- INKT N/A
- BCAB N/A
- P/E Ratio
- INKT N/A
- BCAB N/A
- Revenue Growth
- INKT N/A
- BCAB N/A
- 52 Week Low
- INKT $4.56
- BCAB $0.24
- 52 Week High
- INKT $13.79
- BCAB $3.53
- Technical
- Relative Strength Index (RSI)
- INKT 39.62
- BCAB 47.24
- Support Level
- INKT $7.23
- BCAB $0.26
- Resistance Level
- INKT $8.59
- BCAB $0.34
- Average True Range (ATR)
- INKT 0.72
- BCAB 0.04
- MACD
- INKT -0.10
- BCAB 0.00
- Stochastic Oscillator
- INKT 0.66
- BCAB 58.18
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.